AI drug development startup Pathos AI raises $237 million in a funding round that values the company at $3 billion. SiliconANGLE reports that Bristol Myers Squibb (BMS) leads the Series E, with participation from multiple returning investors, and cites a roster that includes AstraZeneca, NEA, and General Atlantic.
STAT News adds that the transaction brings together Pathos’ AI drug development efforts with a large Tempus dataset, alongside BMS’s role in developing the resulting therapies. Across the coverage, both outlets emphasize the size and valuation of the round and position Pathos as using AI in drug discovery, particularly for cancer. The main difference is emphasis: SiliconANGLE highlights the broader investor lineup and the Series E framing, while STAT News foregrounds the collaboration between data, AI analysis, and pharmaceutical development.
